The BioPhorum CGT Environmental Health and Safety (EHS) workstream offers this downloadable template for CGT institutions to use to assess and mitigate biosafety risk for human-derived cell lines susceptible to adventitious agents.
EHS and Biosafety
Viewing related articles
CGT safety data sheet template
Sep 2023 | Cell & Gene Therapy, Deliverable, Deliverables Report, EHS, EHS and Biosafety, POI - Cell and Gene Therapy, Publication
A downloadable template for CGT institutions to use to communicate workplace hazards and assess the risks posed by CGT materials.
The 13-step guide for conducting cell and gene therapy EHS risk assessments
Oct 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, EHS and Biosafety, Publication
This article and template summarize the main steps in a suggested EHS risk assessment process and can form the basis for discussions between a contract manufacturer and client or between production and development departments.
Adeno-associated virus (AAV) viral vector inactivation survey
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, EHS
This member only survey looks to identify the current approaches used in inactivation of AAV viral vectors, the laboratory and large-scale manufacturing, by gathering information on inactivation alternatives to 10% bleach, known risks, issues or restrictions identified and supportive literature where available.
Single-use closed system failures
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, EHS
A BioPhorum member only benchmarking survey to understand industry approaches to evaluating containment of single-use closed system failures resulting in spill, splash or aerosol release.
Risk assessment of cells used in early development
Sep 2021 | Cell & Gene Therapy, EHS, POI - Cell and Gene Therapy, Publication, Raw materials
This paper is the first in a series considering  real-world scenarios where the EHS companion risk assessment template has been completed.  This assessment focuses on cell expansion operations working with the cell line only in R&D labs to develop procedures and controls; it does not include production operations, such as transfection or viral infections.Â